76 related articles for article (PubMed ID: 2746364)
1. Gd-DISIDA--a potential contrast agent for magnetic resonance imaging of the hepatobiliary system.
Saha GB; Bateson BP; Meaney TF; Ng TC; Go RT; MacIntyre WJ; Feiglin DH; O'Donnell JK
J Nucl Med Allied Sci; 1989; 33(1):1-6. PubMed ID: 2746364
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
[TBL] [Abstract][Full Text] [Related]
4. Dose dependency of 99mTc disofenin (DISIDA) in biliary tract imaging.
Najafi A
Int J Rad Appl Instrum B; 1987; 14(6):539-43. PubMed ID: 3429234
[TBL] [Abstract][Full Text] [Related]
5. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
[TBL] [Abstract][Full Text] [Related]
6. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
7. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
Schuhmann-Giampieri G; Schmitt-Willich H; Press WR; Negishi C; Weinmann HJ; Speck U
Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-DTPA enhancement of experimental soft tissue carcinoma and hemorrhage in magnetic resonance imaging.
Pettersson H; Ackerman N; Kaude J; Googe RE; Mancuso AA; Scott KN; Hackett RH; Hager DA; Caballero S
Acta Radiol; 1987; 28(1):75-8. PubMed ID: 2952147
[TBL] [Abstract][Full Text] [Related]
10. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization.
Ogan MD; Schmiedl U; Moseley ME; Grodd W; Paajanen H; Brasch RC
Invest Radiol; 1987 Aug; 22(8):665-71. PubMed ID: 3667174
[TBL] [Abstract][Full Text] [Related]
11. Use of gadolinium-DTPA as a myocardial perfusion agent: potential applications and limitations for magnetic resonance imaging.
Johnston DL; Liu P; Lauffer RB; Newell JB; Wedeen VJ; Rosen BR; Brady TJ; Okada RD
J Nucl Med; 1987 May; 28(5):871-7. PubMed ID: 3572546
[TBL] [Abstract][Full Text] [Related]
12. Quantitative magnetic resonance imaging in assessment of the blood-retinal barrier.
Plehwe WE; McRobbie DW; Lerski RA; Kohner EM
Invest Ophthalmol Vis Sci; 1988 May; 29(5):663-70. PubMed ID: 3366561
[TBL] [Abstract][Full Text] [Related]
13. [Changes in tissue T1 of brain tumor following GD-DTPA administration--differences in T1 time course and tissue-blood ratio by histological types].
Yoshida K; Furuse M; Kaneoke Y; Sasou K; Motegi Y
No To Shinkei; 1988 Jun; 40(6):531-7. PubMed ID: 3224029
[TBL] [Abstract][Full Text] [Related]
14. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
16. Multinuclear MR characterization of a new hepatobiliary contrast agent. Preliminary results.
Vander Elst L; Maton F; Laurent S; Seghi F; Muller RN
Acta Radiol Suppl; 1997; 412():135-8. PubMed ID: 9240092
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-phthalein complexone as a contrast agent for hepatobiliary MR imaging.
Kawamura Y; Endo K; Koizumi M; Watanabe Y; Saga T; Konishi J; Horiuchi K; Yokoyama A
J Comput Assist Tomogr; 1989; 13(1):67-70. PubMed ID: 2910950
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma: relationship between detectability and tumor differentiation.
Calvet X; Pons F; Bruix J; Bru C; Lomeña F; Herranz R; Brugera M; Faus R; Rodes J
J Nucl Med; 1988 Dec; 29(12):1916-20. PubMed ID: 2848112
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents.
Marinelli ER; Neubeck R; Song B; Wagler T; Ranganathan RS; Sukumaran K; Wedeking PW; Nunn A; Runge VM; Tweedle MF
Invest Radiol; 2000 Jan; 35(1):8-24. PubMed ID: 10639032
[TBL] [Abstract][Full Text] [Related]
20. X-ray fluorescence elemental mapping and microscopy to follow hepatic disposition of a Gd-based magnetic resonance imaging contrast agent.
Delfino R; Altissimo M; Menk RH; Alberti R; Klatka T; Frizzi T; Longoni A; Salomè M; Tromba G; Arfelli F; Clai M; Vaccari L; Lorusso V; Tiribelli C; Pascolo L
Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):834-45. PubMed ID: 21957877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
